StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] by Quarter

PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4]: -12.9% in Q4 2021, up 16.6 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2021
-12.9%
Period ended Jan 2, 2022
Change on a year earlier
+16.6 pts
-29.5% in Q4 2020
History
17 quarters
Since Q4 2017
Sources
17
Documents cited below

Where the Q4 2021 figure comes from

“|| WW | 113 | 129 | (12.9) | (12.2) | (0.7)”

Source: Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — Worldwide reported growth YoY (%) (%)Year on yearSource
Q4 2021Jan 2, 2022-12.9%+16.6 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
Q3 2021Oct 3, 2021-14.6%+18.7 ptsForm 8-K (a2021q3exhibit991.htm, filed 2021-10-19) ↗
Q2 2021Jul 4, 2021-6.6%+19.0 ptsForm 8-K (a2021q2exhibit991final.htm, filed 2021-07-21) ↗
Q1 2021Apr 4, 2021-18.2%+13.4 ptsForm 8-K (a2021q1exhibit991final.htm, filed 2021-04-20) ↗
Q4 2020Jan 3, 2021-29.5%-12.5 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 2020-33.3%-10.9 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 2020-25.6%-2.9 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 2020-31.6%-13.6 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 2019-17.0%-12.3 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
Q3 2019Sep 29, 2019-22.4%-29.5 ptsForm 8-K (a2019q3exhibit991.htm, filed 2019-10-15) ↗
Q2 2019Jun 30, 2019-22.7%-15.2 ptsForm 8-K (a2019q2exhibit9915.htm, filed 2019-07-16) ↗
Q1 2019Mar 31, 2019-18.0%-29.7 ptsForm 8-K (a2019q1exhibit9915.htm, filed 2019-04-16) ↗
Q4 2018Dec 30, 2018-4.7%+5.7 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
Q3 2018Sep 30, 20187.1%–Form 8-K (a8k2018q3exhibit9915.htm, filed 2018-10-16) ↗
Q2 2018Jul 1, 2018-7.5%–Form 8-K (a8k2018q2exhibit9915.htm, filed 2018-07-17) ↗
Q1 2018Apr 1, 201811.7%–Form 8-K (a8k2018q1exhibit9915.htm, filed 2018-04-17) ↗

Cite this data

StockData. (2026). Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] (%), quarterly Q4 2017–Q4 2021 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-procrit-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.